Welcome to our dedicated page for Inari Medical news (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical stock.
Inari Medical, Inc. (NASDAQ: NARI) is a medical device company focused on treating and transforming the lives of patients suffering from venous and other vascular diseases. This news page aggregates company announcements, clinical trial updates, financial disclosures, and event participation related to NARI stock.
Inari’s news often highlights developments around its thrombectomy technologies and venous interventions. The company has reported on clinical research programs such as the ClotTriever CLOUT Registry for deep vein thrombosis and randomized controlled trials including DEFIANCE and PEERLESS. For example, Inari announced positive PEERLESS results comparing its FlowTriever system to catheter-directed thrombolytics in intermediate-risk pulmonary embolism, with outcomes related to clinical deterioration, ICU use, hospital stay, and readmissions.
Investors and healthcare professionals can use this page to follow updates on regulatory and reimbursement milestones, such as national reimbursement approval in Japan for the ClotTriever Thrombectomy System for DVT and related distribution agreements. News items also cover international initiatives like Inari’s joint venture in Greater China with 6 Dimensions Capital, 120 Capital, and VFLO Medical to expand access to its technologies.
In addition, the feed includes information on Inari’s participation in major healthcare and investor conferences, including presentations at the J.P. Morgan Healthcare Conference, the Jefferies London Healthcare Conference, and analyst and investor meetings aligned with key clinical trial presentations. Financial news, such as quarterly results and guidance updates, is also featured. For ongoing insight into NARI’s clinical, commercial, and corporate developments, readers can consult this page as a centralized source of Inari Medical news.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.